



# The SAPIEN 3 Ultra RESILIA Valve Is Designed to Further Elevate Long-Term Durability and Valve Performance<sup>7,9</sup>



Advanced calcium-blocking tissue technology<sup>8</sup>




Taller,\* textured outer skirt extended to 29 mm valve




Only Transcatheter heart valve with dry tissue storage

RESILIA tissue effectively addresses calcification, a leading cause of tissue valve failure<sup>7</sup>



See SAPIEN Platform long-term data at: [heartvalves.com](http://heartvalves.com)



\*Compared to the SAPIEN 3 transcatheter valve.


Expert opinions, advice and all other information expressed represent contributors' views and not necessarily those of Edwards Lifesciences. Clinical data on surgical valves with RESILIA tissue up to 7-year follow-up have been published, with additional follow-up to 10 years in progress.<sup>7</sup> Medical device for professional use. For a listing of indications, contraindications, precautions, warnings, and potential adverse events, please refer to the Instructions for Use (consult [eifl.edwards.com](http://eifl.edwards.com) where applicable). Edwards, Edwards Lifesciences, the stylized E logo, Edwards SAPIEN, Edwards SAPIEN 3, Edwards SAPIEN 3 Ultra, PARTNER, PARTNER II, PARTNER 3, RESILIA, SAPIEN, SAPIEN 3, SAPIEN 3 Ultra and the PARTNER design logo are trademarks or service marks of Edwards Lifesciences Corporation. All other trademarks are the property of their respective owners. © 2026 Edwards Lifesciences Corporation. All rights reserved. PP-EU-11549 v1.0

Edwards Lifesciences Sàrl • Route de l'Etraz 70, 1260 Nyon, Switzerland • [edwards.com](http://edwards.com)

Outcomes from the PARTNER trials:  
**SAPIEN3 TAVI Demonstrates Excellent Long-Term Durability and Valve Performance Comparable to SAV Out to 7 and 10 Years<sup>1,2</sup>**




Edwards




## The PARTNER Trials: 20 Years of Advances in TAVI Evidence Generation and Care for Severe Aortic Stenosis Patients<sup>1,3,4</sup>

### The PARTNER 3 Trial Design<sup>1</sup>




### The PARTNER 2A and S3i Study Designs<sup>2</sup>




## Mortality Outcomes With SAPIEN 3 TAVI Were Comparable to SAVR at 7 and 10 Years

### The PARTNER 3 Low-Risk Trial: 7-Year Follow-Up<sup>\*1</sup>



### The PARTNER 2 S3i Intermediate-Risk Study: 10-Year Follow-Up<sup>\*1</sup>




## SAPIEN 3 TAVI Demonstrated Excellent Long-Term Durability and Valve Performance at 7 and 10 Years

### The PARTNER 3 Trial: AV Reintervention Rates at 7 Years<sup>1</sup>



### The PARTNER 2 S3i Study: AV Reintervention Rates at 10 Years<sup>2</sup>



*In The PARTNER 3 Low-Risk Trial, we again see the early clinical benefit of TAVR with SAPIEN 3 over surgery, as well as excellent long-term valve performance and durability results for both therapies at 7 years, which should be reassuring to patients and their physicians.<sup>5</sup>*

*A reintervention rate with the SAPIEN 3 valve was low and comparable to SAVR at both 7 and 10 years in both trials.<sup>1,2</sup> With this older generation valve, the leading causes of reintervention were stenosis and PVL.<sup>1,2</sup>*

\*Includes patients evaluable for the primary composite endpoint. Doxas not include VSS data.<sup>1</sup> | AT=as treated; TA=transapical; TAO=transaortic; TF=transfemoral; VSS=vital status sweep.

<sup>1</sup>Includes VSS data. VSS was performed by sites on patients who withdrew, were lost to follow-up, did not re-consent, or missed a visit.<sup>1,2</sup> | <sup>†</sup> Baseline characteristics of TAVI group | STS=Society of Thoracic Surgeons.